These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 12388634)

  • 41. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.
    Jo YW; Youn YS; Lee SH; Kim BM; Kang SH; Yoo M; Choi EC; Lee KC
    Int J Pharm; 2006 Feb; 309(1-2):87-93. PubMed ID: 16406701
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of a Hyperglycosylated IFN Alfacon-1 (CIFN): Toward Bimonthly or Monthly Dosing for Antiviral Therapies.
    Taylor JS; Zhang Q; Julander JG; Stoycheva AD; Tan H; Moy CV; Chanda S; Symons JA; Beigelman LN; Blatt LM; Hong J
    J Interferon Cytokine Res; 2015 Aug; 35(8):621-33. PubMed ID: 25866898
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impaired antiviral response in human hepatoma cells.
    Keskinen P; Nyqvist M; Sareneva T; Pirhonen J; Melén K; Julkunen I
    Virology; 1999 Oct; 263(2):364-75. PubMed ID: 10544109
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).
    Reddy KR
    Semin Liver Dis; 2004; 24 Suppl 2():33-8. PubMed ID: 15346244
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The interferons: pharmacology, mechanism of action, tolerance and side effects].
    Arnaud P
    Rev Med Interne; 2002 Nov; 23 Suppl 4():449s-458s. PubMed ID: 12481400
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study.
    Bruno R; Sacchi P; Ciappina V; Zochetti C; Patruno S; Maiocchi L; Filice G
    Antivir Ther; 2004 Aug; 9(4):491-7. PubMed ID: 15456079
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys.
    Mager DE; Neuteboom B; Jusko WJ
    Pharm Res; 2005 Jan; 22(1):58-61. PubMed ID: 15771230
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CpG oligodeoxynucleotide induction of antiviral effector molecules in sheep.
    Nichani AK; Kaushik RS; Mena A; Popowych Y; Dent D; Townsend HG; Mutwiri G; Hecker R; Babiuk LA; Griebel PJ
    Cell Immunol; 2004 Jan; 227(1):24-37. PubMed ID: 15051512
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatitis C virus replication is inhibited by 22beta-methoxyolean-12-ene-3beta, 24(4beta)-diol (ME3738) through enhancing interferon-beta.
    Hiasa Y; Kuzuhara H; Tokumoto Y; Konishi I; Yamashita N; Matsuura B; Michitaka K; Chung RT; Onji M
    Hepatology; 2008 Jul; 48(1):59-69. PubMed ID: 18459156
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacologic effect of recombinant human IFN-alpha, continuously released from a matrix prepared from a polyglycerol ester of fatty acids, on 2',5'-oligoadenylate synthetase activity in murine liver.
    Yamagata Y; Yuasa Y; Yamamoto K; Okamoto K; Igari Y; Iga K; Ogawa Y
    J Interferon Cytokine Res; 2000 Feb; 20(2):153-60. PubMed ID: 10714550
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preparation and characterization of a potent, long-lasting recombinant human serum albumin-interferon-alpha2b fusion protein expressed in Pichia pastoris.
    Huang YS; Chen Z; Yang ZY; Wang TY; Zhou L; Wu JB; Zhou LF
    Eur J Pharm Biopharm; 2007 Sep; 67(2):301-8. PubMed ID: 17418549
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys.
    Zia-Amirhosseini P; Minthorn E; Benincosa LJ; Hart TK; Hottenstein CS; Tobia LA; Davis CB
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1060-7. PubMed ID: 10565825
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interferon and 2',5'-oligo(A) synthetase activities in serum and blood mononuclear leukocytes of cattle after injection of bovine interferon-alpha 1.
    Perino LJ; Short EC; Burge LJ; Winter DA; Fulton RW
    Am J Vet Res; 1990 Jun; 51(6):886-92. PubMed ID: 1695068
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.
    Sarrazin C; Rouzier R; Wagner F; Forestier N; Larrey D; Gupta SK; Hussain M; Shah A; Cutler D; Zhang J; Zeuzem S
    Gastroenterology; 2007 Apr; 132(4):1270-8. PubMed ID: 17408662
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chronopharmacological study of interferon-alpha in mice.
    Koyanagi S; Ohdo S; Yukawa E; Higuchi S
    J Pharmacol Exp Ther; 1997 Oct; 283(1):259-64. PubMed ID: 9336331
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers.
    García-García I; Hernández-González I; Díaz-Machado A; González-Delgado CA; Pérez-Rodríguez S; García-Vega Y; Campos-Mojena R; Tuero-Iglesias ÁD; Valenzuela-Silva CM; Cruz-Ramírez A; Martín-Trujillo A; Santana-Milián H; López-Saura PA; Bello-Rivero I;
    BMC Pharmacol Toxicol; 2016 Dec; 17(1):58. PubMed ID: 27923408
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Half-life extension of porcine interferon-α by fusion to the IgG-binding domain of streptococcal G protein.
    Zong Y; Tan X; Xiao J; Zhang X; Xia X; Sun H
    Protein Expr Purif; 2019 Jan; 153():53-58. PubMed ID: 30165247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.
    Kim KI; Kim SR; Sasase N; Taniguchi M; Harada S; Kinoshita K; Kim SH; Akimoto Y; Shikata M; Kimura N; Izawa S; Ohtani A; Nakao K; Motojima M; Kinoshita M; Hirai M; Ohzu M; Hirooka T; Nabeshima S; Ishii F; Tanaka K; Hotta H
    J Clin Pharm Ther; 2006 Oct; 31(5):441-6. PubMed ID: 16958821
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The induction of prolonged myelopoietic effects in monkeys by GW003, a recombinant human granulocyte colony-stimulating factor genetically fused to recombinant human albumin.
    Xu X; Yang J; Liu Y; Shan C; Wang Q; Chen Z; Cheng Y
    J Pharm Sci; 2015 Feb; 104(2):760-7. PubMed ID: 25174614
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pyridine-2,6-dicarboxaldehyde-Enabled N-Terminal In Situ Growth of Polymer-Interferon α Conjugates with Significantly Improved Pharmacokinetics and In Vivo Bioactivity.
    Sun J; Liu X; Guo J; Zhao W; Gao W
    ACS Appl Mater Interfaces; 2021 Jan; 13(1):88-96. PubMed ID: 33382581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.